Vorasidenib + Lomustine for Brain Cancer

(VALIENT Trial)

This trial aims to determine a safe and tolerable dose of a drug combination: vorasidenib (an experimental treatment) and lomustine (a chemotherapy drug), for treating certain brain cancers called IDH mutant gliomas. Researchers hope these drugs will work well together in future studies to help manage these recurrent brain tumors. The trial seeks participants diagnosed with IDH mutant oligodendroglioma or astrocytoma, who have undergone at least one surgery and have already tried other standard treatments like radiation or chemotherapy.

As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial requires that you stop taking certain medications before starting the study. Specifically, you must not be on therapeutic doses of steroids above a certain level and should not be taking medications that interact with the study drugs. It's best to discuss your current medications with the study team to see if any changes are needed.

Research has shown that vorasidenib, when used alone, produces promising results in patients with IDH-mutant glioma, a type of brain cancer. In these patients, vorasidenib improved outcomes without causing serious side effects. Another study combined vorasidenib with temozolomide and found no serious side effects or negative reactions that would prevent increasing the dose.

Lomustine, a chemotherapy drug, has been used for many years to treat brain tumors. Its side effects are well-known, and it is generally well-tolerated at the doses used in medical settings.

Researchers are excited about Vorasidenib combined with Lomustine for treating brain cancer because it brings a fresh approach to tackling the disease. Unlike traditional treatments that often rely on surgery, radiation, or chemotherapy alone, Vorasidenib targets specific enzymes in the cancer cells, potentially reducing tumor growth more effectively. This unique mechanism of action, combined with Lomustine, might offer better outcomes with possibly fewer side effects. By specifically targeting the cancer's biology, this combination could lead to more precise and powerful treatments than current options like temozolomide or radiation therapy.

Research has shown that vorasidenib may help treat IDH-mutant gliomas, a type of brain cancer. For patients with grade 2 IDH-mutant gliomas, vorasidenib significantly slowed disease progression. Specifically, only 32% of patients taking vorasidenib experienced disease worsening, compared to 64% of those on a placebo. In this trial, participants will receive a combination of vorasidenib and lomustine. An earlier study found that when vorasidenib was combined with lomustine, patients lived for a median of 23.4 months, slightly longer than with lomustine alone. These findings suggest that vorasidenib, especially when used with lomustine, could effectively manage certain brain cancers.¹²³⁵⁶